Hepion pharmaceuticals announces receipt of delisting notification from nasdaq

Morristown, n.j., may 12, 2025 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (covid/influenza a/b and rsv), h. pylori and hcc, today announced that on may 9, 2025, the company received written notice (the “notice”) from the office of general counsel of the nasdaq stock market (“nasdaq”) indicating that the nasdaq hearings panel has determined to delist the company's shares from nasdaq due to the company's failure to meet nasdaq's continued listing standards. as previously disclosed, the company has not been compliant with the requirements under nasdaq listing rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and nasdaq listing rule 5101 indicating that nasdaq believes the company is a public shell. the notice indicated that trading in the company's shares of common stock (the “common stock”) on nasdaq will be suspended effective at the open of trading on tuesday, may 13, 2025.
NDAQ Ratings Summary
NDAQ Quant Ranking